+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance

Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance

Malaria Journal 9: 8

Molecular monitoring of parasite resistance has become an important complementary tool in establishing rational anti-malarial drug policies. Community surveys provide a representative sample of the parasite population and can be carried out more rapidly than accrual of samples from clinical cases, but it is not known whether the frequencies of genetic resistance markers in clinical cases differ from those in the overall population, or whether such community surveys can provide good predictions of treatment failure rates. Between 2003 and 2005, in vivo drug efficacy of amodiaquine or chloroquine plus sulphadoxine-pyrimethamine was determined at three sites in Papua New Guinea. The genetic drug resistance profile (i.e., 33 single nucleotide polymorphisms in Plasmodium falciparum crt, mdr1, dhfr, dhps, and ATPase6) was concurrently assessed in 639 community samples collected in the catchment areas of the respective health facilities by using a DNA microarray-based method. Mutant allele and haplotype frequencies were determined and their relationship with treatment failure rates at each site in each year was investigated. PCR-corrected in vivo treatment failure rates were between 12% and 28% and varied by site and year with variable longitudinal trends. In the community samples, the frequencies of mutations in pfcrt and pfmdr1 were high and did not show significant changes over time. Mutant allele frequencies in pfdhfr were moderate and those in pfdhps were low. No mutations were detected in pfATPase6. There was much more variation between sites than temporal, within-site, variation in allele and haplotype frequencies. This variation did not correlate well with treatment failure rates. Allele and haplotype frequencies were very similar in clinical and community samples from the same site. The relationship between parasite genetics and in vivo treatment failure rate is not straightforward. The frequencies of genetic anti-malarial resistance markers appear to be very similar in community and clinical samples, but cannot be used to make precise predictions of clinical outcome. Thus, indicators based on molecular data have to be considered with caution and interpreted in the local context, especially with regard to prior drug usage and level of pre-existing immunity. Testing community samples for molecular drug resistance markers is a complementary tool that should help decision-making for the best treatment options and appropriate potential alternatives.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 035510274

Download citation: RISBibTeXText

PMID: 20053293

DOI: 10.1186/1475-2875-9-8

Related references

An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes. Methods 97: 51-57, 2016

Temporal changes (1997-2012) of perfluoroalkyl acids and selected precursors (including isomers) in Swedish human serum. Environmental Pollution 199: 166-173, 2015

Treatment of a coronary bifurcation lesion with drug-coated balloons lumen enlargement and plaque modification after 6 months. Clinical Research in Cardiology 102(6): 469-472, 2013

Molecular assessment of Plasmodium falciparum resistance to antimalarial drugs in China. Tropical Medicine and International Health 14(10): 1266-1271, 2009

Modelling the agricultural mechanization for Sanliurfa-Harran region of the Southeastern Anatolian project. Doga Turk Tarm ve Ormanelk Dergisi 13(3A): 858-869, 1989

Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitology Research 109(1): 133-138, 2011

Molecular markers in pediatric neuro-oncology. Neuro-Oncology 14(Suppl. 4): Iv90-Iv99, 2012

Plasmodium falciparum parasitaemia and malaria among pregnant women at first clinic visit in the mount Cameroon Area. Bmc Infectious Diseases 15: 439, 2015

Resistance of Plasmodium falciparum in vivo to 3 days' treatment with quinine and single-dose Fansidar. Papua and New Guinea Medical Journal 37(1): 54-56, 1994

The effect of anti-inflammatory properties of ferritin light chain on lipopolysaccharide-induced inflammatory response in murine macrophages. Biochimica et Biophysica Acta 1843(11): 2775-2783, 2014

The effect of anti-erythrocytic antibodies upon Plasmodium berghei infections in white mice. American Journal of Tropical Medicine and Hygiene 9: 293-296, 1960

Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: a pilot study. Journal of Clinical Lipidology 9(1): 42-48, 2015

Chloroquine resistance in malaria variations of substrate stimulated chloroquine accumulation. Journal of Pharmacology and Experimental Therapeutics 195(3): 389-396, 1975